ATRIO HEALTH PLANS

Anti-Neoplastic: B-Cell Lymphoma Drugs

Besponsa (inotuzumab ozogam) J9229, Columvi (glofitamab-gxbm) J9286, Blincyto (blinatumomab) J9039, Campath/Lemtrada (alemtuzumab) J0202, Polivy (polatuzumab) J9309, Epkinly (epocoritamab-bysp) J9321, Zynlonta (loncastuximab tesirine-lpyl) J9359, Yescarta (Axicabtagene ciloleucel) Q2041

Prior Authorization Request
Medicare Part B Form

*Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.*

☐	**Standard Request– (72 Hours)**	☐	**Urgent Request** (standard time frame could place the member's life, health or ability in serious jeopardy)
	Date Requested _____		
	Requestor _____ Clinic name: _____ Phone / Fax		

MEMBER INFORMATION

*Name:_____ *ID#:_____ *DOB:_____

PRESCRIBER INFORMATION

*Name:_____ ☐MD ☐FNP ☐DO ☐NP ☐PA *Phone:_____

*Address:_____ *Fax:_____

DISPENSING PROVIDER / ADMINISTRATION INFORMATION

*Name:_____ Phone:_____

*Address:_____ Fax:_____

PROCEDURE / PRODUCT INFORMATION

HCPC Code	Name of Drug	Dose (Wt: _____ kg Ht:_____)	Frequency	End Date if known

☐ **Self-administered** ☐ **Provider-administered** ☐ **Home Infusion**

☐Chart notes attached. **Other important information:**_____

Diagnosis: ICD10: _____ **Description**: _____

☐ Provider attests the diagnosis provided is an FDA-Approved indication for this drug

CLINICAL INFORMATION

☐ New Start or Initial Request: (Clinical documentation required for all requests)

☐ **Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria.**

If not, please provide **clinical rationale** for formulary exception: _____

_____

☐ Continuation Requests: (Clinical documentation required for all requests)

☐ **Provider has reviewed the attached "Criteria for Continuation" and attests the member meets ALL required PA Continuation criteria.**

☐ Patient had an adequate response or significant improvement while on this medication.

If not, please provide clinical rationale for continuing this medication: _____

_____

ACKNOWLEDGEMENT

Request By (Signature Required): _____Date:_____ /____ /____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties. **THIS AUTHORIZATION IS NOT A GUARANTEE OF PAYMENT.** PAYMENT IS BASED ON BENEFITS IN EFFECT AT THE TIME OF SERVICE, MEMBER ELIGIBILITY AND MEDICAL NECESSITY.

Prior Authorization Group – Oncology: B-Cell Lymphoma Drugs PA

Drug Name(s):

BESPONSA	**BLINCYTO**
CAMPATH	**LEMTRADA**
POLIVY	**ZYNLONTA**
YESCARTA	**AXICABTAGENE CILOLEUCEL**
COLUMVI	**EPKINLY**

Criteria for approval of Prior Authorization Drug:

1. Prescribed for an approved FDA diagnosis (as listed below):
2. Prescribed by, or in consultation with an oncologist or other cancer specialist related to the diagnosis.
3. Drug is being used appropriately per CMS recognized compendia, authoritative medical literature, evidence-based guidelines and/or accepted standards of medical practice.
4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.

- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

Cannot be prescribed for experimental or investigational use.

Prescriber Restrictions:

Oncologist or other cancer specialist
Lemtrada: Neurologist, Oncologist or other relevant specialist

Coverage Duration:

New Start: Approval will be for 6 months
Continuation: Approval will be for 12 months

FDA Indications:

Besponsa

- Precursor B-cell acute lymphoblastic leukemia, relapsed or refractory

Blincyto

- B-cell acute lymphoblastic leukemia, CD19-positive disease in first or second complete remission with minimal residual disease-positive (0.1% or greater)
- B-cell acute lymphoblastic leukemia, relapsed or refractory, CD19-positive disease

Campath

- B-cell chronic lymphocytic leukemia, Monotherapy

Lemtrada

- B-cell chronic lymphocytic leukemia variant, Monotherapy
- Relapsing remitting multiple sclerosis (inadequate response to two or more drugs indicated for treatment of MS)

Polivy

- Diffuse large B-cell lymphoma, relapsed or refractory, in combination with bendamustine and a rituximab product, after at least 2 prior therapies

Columvi
- Diffuse large B-cell lymphoma, Relapsed or refractory, not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after 2 or more lines of systemic therapy

Epkinly
- Diffuse large B-cell lymphoma, Relapsed or refractory, not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy

Off-Label Uses:

Campath/Lemtrada
- Autoimmune disease - Cytopenia
- Cardiac transplant rejection; prophylaxis
- Chronic lymphoid leukemia
- Graft versus host disease, In patients receiving allogeneic stem cell transplant for hematologic malignancies, steroid-refractory
- Malignant tumor of lymphoid hemopoietic and related tissue
- Primary cutaneous T-cell lymphoma, Relapsed or refractory
- Rejection of intestine transplant; prophylaxis
- Rejection of pancreas transplant; prophylaxis
- Renal transplant rejection, Induction therapy; Prophylaxis
- T-cell prolymphocytic leukemia

Polivy
- Diffuse large B-cell lymphoma, Intermediate- or high-risk, previously untreated, in combination with cyclophosphamide, DOXOrubicin, predniSONE, and rituximab

Yescarta
- B-cell lymphoma, Large, relapsed or refractory, after 2 or more lines of systemic therapy
- B-cell lymphoma, Large, relapse within 12 months or refractory to first-line chemoimmunotherapy
- Follicular lymphoma, Relapsed or refractory after 2 or more lines of systemic therapy

Zynlonta
- B-cell lymphoma, Large, relapsed or refractory, after 2 or more lines of systemic therapy

Age Restrictions:

Besponsa, Pollivy: Safety and effectiveness not established in pediatric patients

Other Clinical Considerations:

Cancer diagnoses: Criteria as per NCCN or other FDA-approved cancer related guidelines.

Black Box Warning:

Columvi: Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving glofitamab-gxbm. Premedicate before each dose, and initiate treatment with the glofitamab-gxbm step-up dosing schedule to reduce the risk of CRS. Withhold glofitamab-gxbm until CRS resolves or permanently discontinue based on severity.

Black Box Warning:
Epkinly:

- Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving epcoritamab-bysp. Initiate treatment with the epcoritamab-bysp step-up dosing schedule to reduce the incidence and severity of CRS. Withhold epcoritamab-bysp until CRS resolves or permanently discontinue based on severity.
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), including life threatening and fatal reactions, can occur with epcoritamab-bysp. Monitor patients for neurological signs or symptoms of ICANS during treatment. Withhold epcoritamab-bysp until ICANS resolves or permanently discontinue based on severity

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/F51C64/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/D3EB0C/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=932318&contentSetId=100&title=Inotuzumab+Ozogamicin&servicesTitle=Inotuzumab+Ozogamicin&brandName=Besponsa&UserMdxSearchTerm=Besponsa&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/BDF17D/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/FFBBE6/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=931306&contentSetId=100&title=Blinatumomab&servicesTitle=Blinatumomab&brandName=Blincyto&UserMdxSearchTerm=Blincyto&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/B51149/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/6F5D96/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=932690&contentSetId=100&title=Polatuzumab+Vedotin-piiq&servicesTitle=Polatuzumab+Vedotin-piiq&brandName=Polivy&UserMdxSearchTerm=Polivy&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/9BBD0F/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/37CDC7/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=933291&contentSetId=100&title=Loncastuximab+Tesirine-lpyl&servicesTitle=Loncastuximab+Tesirine-lpyl&brandName=Zynlonta&UserMdxSearchTerm=zynlonta&=null#

https://www.micromedexsolutions.com/micromedex2/librarian/CS/57C148/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/94BEEE/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Axicabtagene%20Ciloleucel&UserSearchTerm=Axicabtagene%20Ciloleucel&SearchFilter=filterNone&navitem=searchGlobal#

https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=headerLogout#

https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=headerLogout#